US FDA approves Mesoblast's cell therapy for graft-versus-host disease
The U.S. Food and Drug Administration on Wednesday approved Mesoblast's cell therapy for treating a type of complication that ...
FiercePharma2d
After two rejections, FDA approves Mesoblast's first-of-its-kind cell therapy
More than four years later—and after two rejections from the agency—Mesoblast has finally gained an endorsement from the U.S.
Mesoblast Finally Gets Its Approval In GVHD: Where Now?
Investment risks and competition challenge Mesoblast Limited's recent approval for Remestemcel-L in treating ...
Stockhead on MSN2d
Health Check: Joy as Mesoblast wins its first FDA approval for a stem-cell therapy after decades of trying
After years of trying, Mesoblast has won US FDA approval for its stem-cell therapies to treat the fatal graft-versus-host ...
Mesoblast has received FDA approval for its drug Ryoncil
Mesoblast shareholders are sitting on as much as 10-fold gains for the year, after the US Food and Drug Administration ...
Yahoo Finance2d
FDA approves Mesoblast’s Ryoncil for SR-aGvHD treatment
Mesoblast has gained US Food and Drug Administration (FDA) approval for its mesenchymal stromal cell (MSC) therapy, Ryoncil ...
Top-Notch Biotech Mesoblast Skyrockets On Immune Condition Approval
Mesoblast snagged FDA approval late Wednesday for the first-ever treatment for children with a form of GVHD. The biotech ...
Why the Mesoblast share price is diving 18% after an FDA win
The Mesoblast Ltd (ASX: MSB) share price is taking a dive today. Here’s why the biotech stock is under pressure after ...
Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges
Mesoblast's Ryoncil is now FDA-approved for pediatric SR-aGvHD, marking a milestone in mesenchymal stromal cell therapies in ...
Mesoblast shares rocket on FDA approval, but CEO says risks remain
FDA approval for Mesoblast’s cell therapy used to treat children for complications that can occur during bone marrow ...
Mesoblast to be Added to Nasdaq Biotechnology Index
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its upcoming addition to the Nasdaq ...
Mesoblast’s RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy
RYONCIL (remestemcel-L) is the first MSC product approved by FDA for any indication.RYONCIL is the first FDA-approved therapy for children aged 2 ...